Aquablation of the prostate: a review and update

Claus Roehrborn, Seth Teplitsky, Akhil K. Das

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Invasive procedures, such as transurethral resection of the prostate (TURP), have long been the gold standard therapy for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). In recent years, newer treatment modalities have arisen, such as Aquablation, with similar efficacy and improved adverse event profiles, with particular emphasis on postoperative sexual function. MATERIALS AND METHODS: Aquablation is a new technology that utilizes machine-controlled water jets to ablate the soft tissue of the prostate as determined by the doctor. In this review, we will discuss the techniques currently being used to complete this procedure, the outcomes and safety, and finally, the long term data as well as the adverse events associated with Aquablation. RESULTS: Aquablation is rapidly effective in treating patients with LUTS due to BPH. Critically, in head to head comparison with TURP, Aquablation has equivalent objective results with much shorter resections times, and significantly less sexual side effects. Currently, the literature only reports results extending to 12 months post-procedure, and therefore long term durability of results beyond this time point remains unknown. CONCLUSIONS: Aquablation is a safe and effective option for treating LUTS secondary to BPH. Aquablation is a new surgical option that shows very promising short term results, in particular, due to its short resection time regardless of gland size and low rate of sexual side effects. This technology still requires further investigation to confirm durability and efficacy over time.

Original languageEnglish (US)
Pages (from-to)20-24
Number of pages5
JournalThe Canadian journal of urology
Volume26
Issue number4S1
StatePublished - Aug 1 2019

Fingerprint

Lower Urinary Tract Symptoms
Prostate
Prostatic Hyperplasia
Transurethral Resection of Prostate
Technology
Therapeutics
Safety
Water

ASJC Scopus subject areas

  • Urology

Cite this

Aquablation of the prostate : a review and update. / Roehrborn, Claus; Teplitsky, Seth; Das, Akhil K.

In: The Canadian journal of urology, Vol. 26, No. 4S1, 01.08.2019, p. 20-24.

Research output: Contribution to journalArticle

Roehrborn, C, Teplitsky, S & Das, AK 2019, 'Aquablation of the prostate: a review and update', The Canadian journal of urology, vol. 26, no. 4S1, pp. 20-24.
Roehrborn, Claus ; Teplitsky, Seth ; Das, Akhil K. / Aquablation of the prostate : a review and update. In: The Canadian journal of urology. 2019 ; Vol. 26, No. 4S1. pp. 20-24.
@article{8741037326fe44faa63fc0db85f4ec5e,
title = "Aquablation of the prostate: a review and update",
abstract = "INTRODUCTION: Invasive procedures, such as transurethral resection of the prostate (TURP), have long been the gold standard therapy for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). In recent years, newer treatment modalities have arisen, such as Aquablation, with similar efficacy and improved adverse event profiles, with particular emphasis on postoperative sexual function. MATERIALS AND METHODS: Aquablation is a new technology that utilizes machine-controlled water jets to ablate the soft tissue of the prostate as determined by the doctor. In this review, we will discuss the techniques currently being used to complete this procedure, the outcomes and safety, and finally, the long term data as well as the adverse events associated with Aquablation. RESULTS: Aquablation is rapidly effective in treating patients with LUTS due to BPH. Critically, in head to head comparison with TURP, Aquablation has equivalent objective results with much shorter resections times, and significantly less sexual side effects. Currently, the literature only reports results extending to 12 months post-procedure, and therefore long term durability of results beyond this time point remains unknown. CONCLUSIONS: Aquablation is a safe and effective option for treating LUTS secondary to BPH. Aquablation is a new surgical option that shows very promising short term results, in particular, due to its short resection time regardless of gland size and low rate of sexual side effects. This technology still requires further investigation to confirm durability and efficacy over time.",
author = "Claus Roehrborn and Seth Teplitsky and Das, {Akhil K.}",
year = "2019",
month = "8",
day = "1",
language = "English (US)",
volume = "26",
pages = "20--24",
journal = "The Canadian journal of urology",
issn = "1195-9479",
publisher = "Canadian Journal of Urology",
number = "4S1",

}

TY - JOUR

T1 - Aquablation of the prostate

T2 - a review and update

AU - Roehrborn, Claus

AU - Teplitsky, Seth

AU - Das, Akhil K.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - INTRODUCTION: Invasive procedures, such as transurethral resection of the prostate (TURP), have long been the gold standard therapy for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). In recent years, newer treatment modalities have arisen, such as Aquablation, with similar efficacy and improved adverse event profiles, with particular emphasis on postoperative sexual function. MATERIALS AND METHODS: Aquablation is a new technology that utilizes machine-controlled water jets to ablate the soft tissue of the prostate as determined by the doctor. In this review, we will discuss the techniques currently being used to complete this procedure, the outcomes and safety, and finally, the long term data as well as the adverse events associated with Aquablation. RESULTS: Aquablation is rapidly effective in treating patients with LUTS due to BPH. Critically, in head to head comparison with TURP, Aquablation has equivalent objective results with much shorter resections times, and significantly less sexual side effects. Currently, the literature only reports results extending to 12 months post-procedure, and therefore long term durability of results beyond this time point remains unknown. CONCLUSIONS: Aquablation is a safe and effective option for treating LUTS secondary to BPH. Aquablation is a new surgical option that shows very promising short term results, in particular, due to its short resection time regardless of gland size and low rate of sexual side effects. This technology still requires further investigation to confirm durability and efficacy over time.

AB - INTRODUCTION: Invasive procedures, such as transurethral resection of the prostate (TURP), have long been the gold standard therapy for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). In recent years, newer treatment modalities have arisen, such as Aquablation, with similar efficacy and improved adverse event profiles, with particular emphasis on postoperative sexual function. MATERIALS AND METHODS: Aquablation is a new technology that utilizes machine-controlled water jets to ablate the soft tissue of the prostate as determined by the doctor. In this review, we will discuss the techniques currently being used to complete this procedure, the outcomes and safety, and finally, the long term data as well as the adverse events associated with Aquablation. RESULTS: Aquablation is rapidly effective in treating patients with LUTS due to BPH. Critically, in head to head comparison with TURP, Aquablation has equivalent objective results with much shorter resections times, and significantly less sexual side effects. Currently, the literature only reports results extending to 12 months post-procedure, and therefore long term durability of results beyond this time point remains unknown. CONCLUSIONS: Aquablation is a safe and effective option for treating LUTS secondary to BPH. Aquablation is a new surgical option that shows very promising short term results, in particular, due to its short resection time regardless of gland size and low rate of sexual side effects. This technology still requires further investigation to confirm durability and efficacy over time.

UR - http://www.scopus.com/inward/record.url?scp=85071772129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071772129&partnerID=8YFLogxK

M3 - Article

C2 - 31481145

AN - SCOPUS:85071772129

VL - 26

SP - 20

EP - 24

JO - The Canadian journal of urology

JF - The Canadian journal of urology

SN - 1195-9479

IS - 4S1

ER -